NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $2.72 -0.15 (-5.05%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$2.72 0.00 (-0.18%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alto Neuroscience Stock (NYSE:ANRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$2.71▼$2.9050-Day Range$1.81▼$3.0552-Week Range$1.60▼$17.55Volume117,411 shsAverage Volume383,894 shsMarket Capitalization$73.77 millionP/E RatioN/ADividend YieldN/APrice Target$15.40Consensus RatingModerate Buy Company OverviewAlto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Read More… Alto Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreANRO MarketRank™: Alto Neuroscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 768th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlto Neuroscience has only been the subject of 3 research reports in the past 90 days.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alto Neuroscience is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alto Neuroscience is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alto Neuroscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.01% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Alto Neuroscience has recently decreased by 7.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.01% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Alto Neuroscience has recently decreased by 7.67%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.54 News SentimentAlto Neuroscience has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alto Neuroscience this week, compared to 2 articles on an average week.Search Interest8 people have searched for ANRO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address ANRO Stock News HeadlinesAlto Neuroscience to Participate in Upcoming Investor ConferencesMay 28 at 8:03 AM | businesswire.comHC Wainwright Has Bearish Estimate for ANRO Q2 EarningsMay 23, 2025 | americanbankingnews.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 29, 2025 | Golden Portfolio (Ad)William Blair Analysts Reduce Earnings Estimates for ANROMay 20, 2025 | americanbankingnews.comQ2 Earnings Estimate for Alto Neuroscience Issued By WedbushMay 19, 2025 | americanbankingnews.comAlto Neuroscience Advances Precision Psychiatry PipelineMay 16, 2025 | tipranks.comAlto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | finance.yahoo.comAlto Neuroscience Stock Short Interest Report | NYSE:ANRO | BenzingaMay 10, 2025 | benzinga.comSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $4.23 on January 1st, 2025. Since then, ANRO shares have decreased by 35.6% and is now trading at $2.7250. View the best growth stocks for 2025 here. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $16.00 per share. Who are Alto Neuroscience's major shareholders? Top institutional investors of Alto Neuroscience include Armistice Capital LLC (5.91%), AWM Investment Company Inc. (3.33%), Woodline Partners LP (1.33%) and Almitas Capital LLC (0.87%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alto Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/13/2025Today5/29/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$15.40 High Stock Price Target$43.00 Low Stock Price Target$4.00 Potential Upside/Downside+465.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.28% Return on Assets-33.52% Debt Debt-to-Equity Ratio0.05 Current Ratio13.10 Quick Ratio13.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares27,072,000Free FloatN/AMarket Cap$73.77 million OptionableN/A Beta1.87 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:ANRO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.